GLUCOSYN 150 is a synthetic peptide analog designed to modulate glucose metabolism, enhance insulin sensitivity, and support stable energy levels. Inspired by naturally occurring incretin mimetics and metabolic regulators such as GLP-1, Amylin, and C-Peptide fragments, this peptide was developed to offer multifaceted support for blood sugar balance, fat loss, and metabolic resilienceāespecially in the context of insulin resistance, pre-diabetes, or physique optimization.
The development of GLUCOSYN 150 stems from research into multi-domain peptides that simultaneously address glucose uptake, hepatic glucose production, and mitochondrial efficiency. Its sequence is optimized for:
- AMPK pathway activation, mimicking cellular effects of calorie restriction and exercise.
- Improved GLUT4 translocation, allowing more efficient glucose uptake in muscle cells.
- Suppression of hepatic gluconeogenesis, reducing blood sugar spikes.
- Reduction of postprandial insulin spikes, promoting metabolic flexibility.
Unlike synthetic GLP-1 analogs, GLUCOSYN 150 is designed to avoid nausea and gastrointestinal side effects, while still supporting fat loss, stable energy, and enhanced nutrient partitioning.
Backed by Research
- Peptide AMPK Activators: A 2020 study by Coughlan et al. described how peptide-based AMPK agonists improve glucose homeostasis and mitochondrial function (Diabetologia, 63: 184ā197).
- Peptides Enhancing GLUT4: Research from Shashkin et al. (2017) highlighted the role of synthetic peptides in increasing GLUT4 expression and muscle glucose uptake (J Endocrinol, 234(2): 127ā136).
- Dual-action Metabolic Peptides: A 2022 meta-analysis by Zhang et al. supported the use of hybrid peptides for improving insulin sensitivity and reducing visceral fat (Metabolism, 123: 154848).
References
Coughlan, K. A., Valentine, R. J., Ruderman, N. B., & Saha, A. K. (2020). AMPK activation: a therapeutic target for type 2 diabetes? Diabetologia, 63(2), 184ā197. https://doi.org/10.1007/s00125-019-05022-3
Shashkin, P. N., Orekhov, A. N., & Bobryshev, Y. V. (2017). Synthetic peptides as potential regulators of glucose transporter expression in skeletal muscle. Journal of Endocrinology, 234(2), 127ā136. https://doi.org/10.1530/JOE-17-0042
Zhang, L., Li, Y., & Zhao, J. (2022). Dual and multi-receptor agonist peptides in the treatment of obesity and metabolic disorders: A systematic review and meta-analysis. Metabolism, 123, 154848. https://doi.org/10.1016/j.metabol.2021.154848
-01K9SEBAY8W7FNE78W1YY1VNXV.png&w=3840&q=75)
-01K9SEZ6YZZVBK7FXQCV1W1CBE.png&w=3840&q=75)
-01K9SPZRFM3EBE8EEHE5CZCK4H.png&w=3840&q=75)
-01K9SF9E33JJ14KKXN5S1WAY2D.png&w=3840&q=75)
-01K9SPAYBT2HBQ0R17MHYZ1ZPP.png&w=3840&q=75)
-01K9SP7JR2NX45C4RV7X5046ZB.png&w=3840&q=75)
-01K9SFHS7CP39AYTS9RNQD8MGV.png&w=3840&q=75)
-01K9SP6N6EHJQS3XSMRM8EAQGE.png&w=3840&q=75)
